| Literature DB >> 33363541 |
Neil Halliday1,2, Cayman Williams1, Alan Kennedy1, Erin Waters1, Anne M Pesenacker1, Blagoje Soskic1, Claudia Hinze1, Tie Zheng Hou1, Behzad Rowshanravan1, Daniel Janman1, Lucy S K Walker1, David M Sansom1.
Abstract
CD80 and CD86 are expressed on antigen presenting cells and are required to engage their shared receptor, CD28, for the costimulation of CD4 T cells. It is unclear why two stimulatory ligands with overlapping roles have evolved. CD80 and CD86 also bind the regulatory molecule CTLA-4. We explored the role of CD80 and CD86 in the homeostasis and proliferation of CD4+FoxP3+ regulatory T cells (Treg), which constitutively express high levels of CTLA-4 yet are critically dependent upon CD28 signals. We observed that CD86 was the dominant ligand for Treg proliferation, survival, and maintenance of a regulatory phenotype, with higher expression of CTLA-4, ICOS, and OX40. We also explored whether CD80-CD28 interactions were specifically compromised by CTLA-4 and found that antibody blockade, clinical deficiency of CTLA-4 and CRISPR-Cas9 deletion of CTLA-4 all improved Treg survival following CD80 stimulation. Taken together, our data suggest that CD86 is the dominant costimulatory ligand for Treg homeostasis, despite its lower affinity for CD28, because CD80-CD28 interactions are selectively impaired by the high levels of CTLA-4. These data suggest a cell intrinsic role for CTLA-4 in regulating CD28 costimulation by direct competition for CD80, and indicate that that CD80 and CD86 have discrete roles in CD28 costimulation of CD4 T cells in the presence of high levels of CTLA-4.Entities:
Keywords: CD28; CD80; CD86; CTLA-4; costimulation; homeostasis; regulatory T cells
Mesh:
Substances:
Year: 2020 PMID: 33363541 PMCID: PMC7753196 DOI: 10.3389/fimmu.2020.600000
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561